| 4EBP1 | Eukaryotic translation initiation factor 4E binding protein 1 |
| AEs | Adverse events |
| AMPK | AMP kinase |
| AMPKβ | AMP activated protein kinaseβ |
| ATP | Adenosine Tri-Phosphate |
| BBN | N-butyl-N-(4-hydroxybutyl) nitrosamine |
| Bgff | Basic fibroblast growth factor |
| CBR | Clinical benefit rate |
| ccRCC | Clear cell renal cell carcinoma |
| chRCC | Chromophobe renal cell carcinoma |
| CRC | Colorectal cancer |
| CRPC | Castration-resistance prostate cancer |
| CSC | Cancer stem cells |
| CT | Chemotherapy |
| DAP1 | Death-associated protein 1 |
| DCR | Disease control rate |
| DEP | EGL-10 and Pleckstrin |
| DEPTOR | DEP domain-containing mTOR-interacting protein |
| EBV | Epstein-Barr virus |
| EGFR | Epidermal Growth Factor Receptor |
| eIF-3 | Eukaryotic initiation factor-3 |
| eIF-4E | Eukaryotic translation Initiation Factor |
| EMT | Epithelial mesenchymal transition |
| ERKs | Extracellular signal-regulated kinases |
| FDA | Food and Drug Administration |
| FKBP12 | FK506 Binding Protein 12 |
| FoxO | Forkhead box family transcription factors |
| GC | Gastric cancer |
| Grb10 | Growth factor receptor-bound protein 10 |
| HER2 | Human epidermal growth factor receptor 2 |
| HIF-1α | Hypoxia-inducible factor 1α |
| HNSCC | Head and neck squamous cell carcinoma |
| HPV | Papilloma virus |
| HR | Hormone Receptor |
| IGFR | Insulin growth factor receptor |
| IRS | Insulin receptor substrate |
| LAR | Long-acting release |
| MAPK | Mitogen activated protein kinase |
| MEK | Mitogen-activated protein kinase kinase |
| MIUBCs | Muscle-invasive UBCs |
| mLST8 | Mammalian lethal with SEC13 protein 8 |
| mRCC | Metastatic renal cell carcinoma |
| mSIN1 | Mammalian stress-activated protein kinase interacting protein 1 |
| mTOR | The mammalian or mechanistic target of rapamycin |
| mTORC | mTOR complex |
| NDRG1 | N-myc Downstream-Regulated Gene 1 protein |
| NF-κB | Nuclear factor-κB |
| NMIUBCs | Non-muscle-invasive UBCs |
| NSCLC | Non-small cell lung cancer |
| OS | Overall survival |
| p-Akt | Phosphor-protein kinase B |
| PCa | Prostate cancer |
| PDGF | Platelet-derived growth factor |
| PDK1 | Phosphoinositide-dependent Kinase 1 |
| PFS | Progression free survival |
| PI3K | Phosphoinositide 3-kinase |
| PIKK | Phosphoinositide 3-kinase related protein kinase |
| PIP3 | Phosphatidylinositol (3, 4, 5)-triphosphate |
| PKA | cAMP-dependent protein kinase |
| PKC | Protein kinase C |
| PKG | cGMP-dependent protein kinase |
| p-mTOR | Phosphorylated-mTOR |
| PP2A | Protein phosphatase 2A |
| PRAS40 | Proline-rich substrate of 40 kDa |
| PRCC | Papillary renal cell carcinoma |
| Protor-1/2 | Protein observed with RICTOR 1/2 |
| PRR 5 | Proline-rich protein 5 |
| p-S6K1 | p70 ribosomal S6 Kinase |
| PTEN | Phosphatase and tensin homolog on chromosome 10 |
| RAPTOR | Regulatory-associated protein of mTOR |
| RCC | Renal cancer |
| REDD1 | DNA damage and development 1 |
| RHEB | Ras homolog enriched in brain |
| RICTOR | Rapamycin-insensitive companion of mTOR |
| RR | Radioresistance |
| RSK | Ribosomal protein S6 kinase |
| S6K | S6 kinase |
| S6RP | S6 ribosomal protein |
| SCLC | Small cell lung cancinoma |
| SGK | Serum glucose kinase |
| SNP | Single-nucleotide polymorphisms |
| SQCLC | Squamous cell lung carcinoma |
| SREBP | Sterol regulatory element-binding protein |
| SRE-BP1 | Sterol regulatory element-binding protein 1 |
| STAT | Signal transducer and activator of transcription |
| STK11 | Serine threonine kinase 11 |
| TCGA | The cancer genome atlas |
| Tel2 | Telomere maintenance 2 |
| TFEB | Transcription factor transcription factor EB |
| TNBC | Triple-negative breast cancer |
| TSC | Tuberous sclerosis complex |
| Tti1 | Tel2-interacting protein 1 |
| TTP | Time to progression |
| UBC | Urinary bladder cancer |
| ULK1 | UNC-5 Like autophagy activating Kinase 1 |
| VEGF | Vascular endothelial growth factor |
| WIPI2 | WD repeat domain phophoinositide-interacting protein 2 |